Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
Authors
Keywords
Triple negative breast cancer (TNBC), CDK 4/6 inhibitor, mTOR inhibitor, Palbociclib, MLN0128, Retinoblastoma protein (pRb)
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-03
DOI
10.1007/s10549-018-05104-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
- (2018) Daniele Cretella et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
- (2018) Chrysiis Michaloglou et al. MOLECULAR CANCER THERAPEUTICS
- ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer
- (2018) Karineh Petrossian et al. Oncotarget
- Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts
- (2017) Leslie R. Euceda et al. JOURNAL OF PROTEOME RESEARCH
- Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2− and ER+HER2+) breast cancers
- (2017) Noriko Kanaya et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
- (2017) Smruthi Vijayaraghavan et al. Nature Communications
- Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells
- (2017) Mara A. Bonelli et al. NEOPLASIA
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
- (2016) Shom Goel et al. CANCER CELL
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
- (2016) Yana Pikman et al. CLINICAL CANCER RESEARCH
- The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
- (2016) Bo Mi Ku et al. Oncotarget
- Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
- (2016) Jorge Franco et al. Cell Reports
- FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2015) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- Palbociclib: First Global Approval
- (2015) Sohita Dhillon DRUGS
- Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
- (2015) Aarthi Kannan et al. Oncotarget
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
- (2012) Yesim Gökmen-Polar et al. BREAST CANCER RESEARCH AND TREATMENT
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2012) A. K. Witkiewicz et al. CLINICAL CANCER RESEARCH
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
- (2012) J C Montero et al. ONCOGENE
- CpG island hypermethylation ofBRCA1and loss of pRb as co-occurring events in basal/triple-negative breast cancer
- (2011) Olafur Andri Stefansson et al. Epigenetics
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Prognostic Significance of Young Age (
- (2011) Eun-Kyu Kim et al. WORLD JOURNAL OF SURGERY
- RB-pathway disruption in breast cancer
- (2010) Adam Ertel et al. CELL CYCLE
- Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
- (2010) Xiaohong R. Yang et al. JNCI-Journal of the National Cancer Institute
- Mitotic Raptor Promotes mTORC1 Activity, G2/M Cell Cycle Progression, and Internal Ribosome Entry Site-Mediated mRNA Translation
- (2010) F. Ramirez-Valle et al. MOLECULAR AND CELLULAR BIOLOGY
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
- High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy
- (2009) D. Trere et al. ANNALS OF ONCOLOGY
- Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004
- (2009) Carol A. Parise et al. Breast Journal
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search